Skip to content

Absolute Flow for Ischemia With No Obstructive Coronary Arteries

Absolute Flow for Ischemia With No Obstructive Coronary Arteries

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05825339
Acronym
AF-INOCA
Enrollment
121
Registered
2023-04-24
Start date
2021-05-01
Completion date
2024-06-30
Last updated
2023-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina, Stable, Coronary Microvascular Disease, Coronary Microvascular Dysfunction

Keywords

Microvascular dysfunction, Coronary circulation, Myocardial ischemia Diagnosis, Coronary flow

Brief summary

The main objective is to prospectively validate the capacity of continuous thermodilution coronary flow reserve (CFRflow) as a predictor of the presence of angina measured by SAQ7 in patients with INOCA at 3 months. Secondary objectives include identifying hemodynamic factors related to the persistence of angina at 3 and 12 months, identifying clinical factors associated with the persistence of angina, establishing the prevalence of patients with coronary microvascular dysfunction within the cohort of INOCA patients, identifying predictors of major cardiovascular events at 12 months, validating the pathological value of MMR and establishing the pathological value of AF measured in ml/min. The study also aims to evaluate the concordance between measures of the coronary microvascular function obtained by continuous thermodilution and bolus thermodilution, as well as their concordance with clinical characteristics.

Detailed description

Invasive study of microvascular function has become highly relevant for the diagnosis of alterations in coronary physiology for diagnostic, prognostic, and therapeutic purposes. Currently, the microvascular resistance index (IMR) is considered the gold standard for invasive diagnosis of coronary microvascular function, with a recommendation of 2A in the current clinical practice guidelines of the European Society of Cardiology. In recent years, technical innovation has allowed for the measurement of absolute coronary flow (AF) and minimal microvascular resistance (MMR) using continuous thermodilution, enabling the determination of quantitative flow and resistance units. However, the main limitation is the absence of reference values. Objectives: The main objective is to prospectively validate the capacity of CFRflow as a predictor of the presence of angina measured by SAQ7 in patients with INOCA at 3 months. Secondary objectives include identifying hemodynamic factors related to the persistence of angina at 3 and 12 months, identifying clinical factors related to the persistence of angina, establishing the prevalence of patients with coronary microvascular dysfunction within the cohort of INOCA patients, identifying predictors of major cardiovascular events at 12 months, validating the pathological value of MMR and establishing the pathological value of AF measured in ml/min. The study also aims to evaluate the concordance between measures of the coronary microvascular function obtained by continuous thermodilution and bolus thermodilution, as well as their concordance with clinical characteristics.

Interventions

DIAGNOSTIC_TESTCoronary Flow Reserve

Diagnostic of Microvascular Coronary Dysfunction using continuous thermodilution flow reserve

Sponsors

Spanish Society of Cardiology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Over 18 years of age, and * Clinical indication for coronary angiography and in whom the use of microvascular function diagnosis by pressure guide is considered clinically necessary. * Clinical diagnosis of typical or atypical angina. * Coronary arteries without lesions or with epicardial lesions \<50% by visual estimation or fractional flow reserve (FFR)\>0.80. * Absence of clinical or anatomical contraindications for the study of microvascular function. Consent for participation in the study prior to information and consent form signature.

Exclusion criteria

* Decompensated heart failure or cardiogenic shock. * Admission due to Acute Coronary Syndrome with an elevation of markers in the month prior to inclusion. * Indication for coronary angioplasty. * Severe pulmonary hypertension. * Obstructive hypertrophic cardiomyopathy. * Severe valvular disease. * Previous allergy or intolerance to adenosine or adenosine triphosphate.

Design outcomes

Primary

MeasureTime frameDescription
Angina StatusAt inclusionAngina Status assessed by Seattle Angina Questionnaire (SAQ).The total score is also transformed into a scale from 0 to 100, where a higher score indicates better angina-related quality of life.

Secondary

MeasureTime frameDescription
Quality of life at 3 months3 monthsQuality of life status in patients at 3 months post-diagnosis measured by the Seattle Angina Questionnaire (SAQ).The total score is also transformed into a scale from 0 to 100, where a higher score indicates better angina-related quality of life.
Accuracy of continuous thermodilution coronary flow reserve (CFR) measured by Youden Index = Sensitivity + Specificity - 1At inclusionContinuous thermodilution measured CFR flow and minimal microvascular resistance (MMR flow).

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026